Related Experiment Video

Updated: Mar 20, 2026

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.8K

Pediatric Obesity-Related Asthma: The Role of Metabolic Dysregulation

Nandini Vijayakanthi1, John M Greally2, Deepa Rastogi3

  • 1Departments of Pediatrics.

Pediatrics
|June 1, 2016
PubMed

Insights

Obesity increases asthma risk in children, especially minorities. Metabolic dysregulation, genetics, and epigenetics are key factors in pediatric obesity-related asthma, requiring further research for prevention.

Area of Science:

  • Pediatric respiratory medicine
  • Obesity and metabolic disorders
  • Immunology and inflammation

Background:

  • Obesity is a significant risk factor for childhood asthma, yet not all obese children develop the condition.
  • Existing research highlights diet, physical activity, mechanical load, and inflammation in obesity-asthma pathophysiology.
  • Understanding specific mechanisms is crucial for addressing health disparities in ethnic minority children.

Purpose of the Study:

  • To review current research on mechanisms linking childhood obesity and asthma.
  • To explore the role of metabolic dysregulation, genetic, and epigenetic factors in pediatric obesity-related asthma.
  • To identify knowledge gaps for developing primary preventive strategies.

Main Methods:

  • Literature review of recent studies on obesity-asthma mechanisms.
  • Analysis of emerging evidence on metabolic dysregulation in pediatric asthma.
  • Examination of genetic and epigenetic influences on susceptibility.

Main Results:

  • Diet, sedentary behavior, mechanical fat load, and adiposity-driven inflammation are implicated in obesity-asthma.
  • Metabolic dysregulation is emerging as a key pathway in pediatric obesity-related asthma.
  • Genetic and epigenetic factors contribute to susceptibility to metabolic issues and lung problems.

Conclusions:

  • Metabolic dysregulation, influenced by genetic and epigenetic factors, is a critical area for understanding pediatric obesity-related asthma.
  • Further research is needed to elucidate specific pathways for effective primary prevention strategies.
  • Addressing obesity-related asthma requires a multifaceted approach considering metabolic, genetic, and environmental factors.

More Related Videos

Assessment of Child Anthropometry in a Large Epidemiologic Study09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

28.0K
Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
315
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
272